Preterm Birth & PROM Testing Market - Global Forecast 2025-2032

The Preterm Birth & PROM Testing Market is undergoing significant transformation as new technologies and changing clinical needs shape diagnostic strategies for preterm birth and premature rupture of membranes. Solutions now enable more rapid and reliable testing, empowering healthcare providers with real-time data to inform timely intervention and treatment planning.

Preterm Birth & PROM Testing Market Snapshot

The global preterm birth and PROM testing market expanded from USD 1.64 billion in 2024 to USD 1.74 billion in 2025 and is projected to reach USD 2.70 billion by 2032, driven by a compound annual growth rate of 6.42%. This momentum is enabled by growing demand for early and precise diagnostic tools, ongoing research innovation, and an increasingly complex clinical landscape. Stakeholders in laboratory diagnostics, medical device manufacturing, and maternal-fetal medicine are progressively focused on integrating advanced immunoassays, molecular diagnostic platforms, and rapid test formats into day-to-day practice.

Scope & Segmentation

• Product Types:
  • Instruments & Equipment: Automated ELISA analyzers, Immunoassay analyzers, PCR systems.
  • Kits & Assay Kits: ELISA kits, PCR test kits, Rapid test kits.
  • Reagents & Consumables: Antibodies, Buffers & media, Enzymes & probes.
• End User Segments:
  • Ambulatory care
  • Diagnostic laboratories
  • Hospitals & clinics
  • Research institutes
• Application Areas:
  • Diagnosis
  • Monitoring
  • Research use
  • Screening
• Geographical Coverage:
  • Americas: North America (United States, Canada, Mexico), Latin America (Brazil, Argentina, Chile, Colombia, Peru)
  • Europe, Middle East & Africa: Europe (United Kingdom, Germany, France, Russia, Italy, Spain, Netherlands, Sweden, Poland, Switzerland), Middle East (United Arab Emirates, Saudi Arabia, Qatar, Turkey, Israel), Africa (South Africa, Nigeria, Egypt, Kenya)
  • Asia-Pacific: China, India, Japan, Australia, South Korea, Indonesia, Thailand, Malaysia, Singapore, Taiwan
• Companies Profiled:
  • Roche Diagnostics GmbH
  • Abbott Laboratories
  • Hologic, Inc.
  • Quidel Corporation
  • Danaher Corporation
  • Thermo Fisher Scientific Inc.
  • bioMérieux SA
  • Sekisui Medical Co., Ltd.
  • Sera Prognostics, Inc.
  • Rhomed S.p.A.

Key Takeaways for Senior Decision-Makers

• Rapid diagnostic tool integration is enabling earlier intervention and streamlined care for mothers at risk of preterm labor and PROM.
• Immunoassay and molecular technology advances support higher testing throughput and improved reliability in both point-of-care and laboratory settings.
• Collaboration between industry leaders, research institutions, and healthcare facilities accelerates the validation of new reagent chemistries and robust assay workflows.
• Strategic supplier agreements and distribution partnerships are essential to mitigate supply chain risk, especially in regions prone to logistical challenges.
• Diversification of pricing and tailored product bundles is supporting better access in cost-sensitive and underserved segments.
• Continuous research enhances biomarker discovery and strengthens clinical application of novel testing modalities.

Tariff Impact on Supply Chains and Cost Structures

Recently announced tariff adjustments in the United States are set to reshape sourcing strategies for critical diagnostic equipment and consumables. Manufacturers importing automated analyzers, PCR systems, and assay reagents must adapt to increased customs duties, prompting supply chain teams to explore diversified production hubs and renegotiate global contracts. End users and distributors may need to build responsive procurement structures—including flexible pricing models—to help absorb cost pressures and maintain uninterrupted product access.

Research Methodology & Data Sources

This report is anchored in a multi-dimensional research approach, combining peer-reviewed literature, expert interviews with clinical and procurement professionals, and systematic review of product registries and regulatory filings. Comprehensive patent analysis and validation by expert advisory panels ensure a robust and balanced perspective on emerging trends and future market direction.

Why This Report Matters

• Reveals actionable strategies to address evolving clinical requirements and technology adoption in preterm birth and PROM diagnostics.
• Equips decision-makers with benchmarks for risk management in the face of supply chain and regulatory changes.
• Offers granular competitive analysis and market entry guidance for established and emerging industry participants.

Conclusion

As diagnostic innovation accelerates, the preterm birth and PROM testing sector is positioned for continued expansion. Stakeholders who prioritize adaptability, collaboration, and operational efficiency can strengthen their market presence and navigate evolving clinical, technological, and economic landscapes with confidence.

Additional Product Information:

• Purchase of this report includes 1 year online access with quarterly updates.
• This report can be updated on request. Please contact our Customer Experience team using the Ask a Question widget on our website.